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See Article, pages 211–219The article by Navarro-Alvarez and colleagues, entitled ‘‘Intra-
muscular transplantation of engineered hepatic tissue constructs
corrects acute and chronic liver failure in mice” [1] and published
in the current issue of Journal of Hepatology, offers an interesting
approach towards the future of cell transplantation and tissue
engineering. These authors investigated whether a non-immnu-
nogenic self-assembling peptide nano-ﬁber (SAPNF), used in
combination with conditioned media (CM) derived from an
immortalized human hepatocyte cell line, was capable of provid-
ing a three dimensional scaffold that allowed hepatocytes to
maintain their function. The experiments were performed in cul-
ture and in vivo after transplantation of engineered tissue within
the skeletal muscle of mice, and the results compared to cells
grown in Matrigel, an extracellular matrix mimicking the physi-
ological growth microenvironment of hepatocytes. A ﬁrst set of
experiments demonstrated that cells grown in SAPNF/CM matrix
kept a mature hepatocyte phenotype, expressing albumin and
cytochrome, and showed signs of de-differentiation such as
expression of CK19 and AFP after 21 days in cultures [1]. SAP-
NF/CM engrafted cells harboured major detoxiﬁcation properties,
and metabolized ammonia, lidocaine, and diazepam more effec-
tively than cells grown in Matrigel. Another set of experiments
using in vivo models of fulminant and chronic hepatitis clearly
established the superiority of SAPNF/CM engrafted hepatocytes
in terms of overall survival rate, decrease of ammonia levels
and encephalopathy [1]. The original locus (within the skeletal
muscle) for cell implantation tested out by the authors allowed
a large number of cell transplantations without the risk of portal
hypertension, thrombosis and pulmonary embolism associated
with intraportal infusion [2]; this deﬁnitely further improved
the quality of the results. On the whole, this work proposes an
elegant and a relatively safe therapeutic procedure that may be
easily scaled up to clinic as an alternative to liver replacement
strategies. A further advantage of polymeric matrices with regard
to cell transplantation is that it provides a reversibility of the sur-
gical act, due to the fact that the transplant can be easily
removed.Journal of Hepatology 20
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ultimate life-saving therapy for numerous end-stage liver dis-
eases such as fulminant or chronic hepatitis and inborn metabolic
disorders. Besides the requirement of a surgical team with an
expertise for this procedure, the shortage in transplantable mate-
rial still limits the organ replacement strategy, which only fulﬁlls
about 20% of the needs. This has raised an interest in developing
alternative approaches to support liver functions, in order to give
a chance for the liver to recover or to stretch out the life expec-
tancy of patients waiting for a donor liver. Among these
approaches, cell and tissue engineered transplantation have
yielded promising results. In recent years, cell transplantation
has been a particularly active area with numerous proofs of con-
cept generated in animal models as well as patients with acute or
chronic liver failure and metabolic disorders (for review see
[3,4]). In the literature, up to 40 patients have been reported to
undergo cell transplantation treatment after having been diag-
nosed with acute liver failure and multiple organ failure – arising
from different aetiologies – and exhibited encouraging results
with regard to ammonia levels as well as measurable improve-
ments of encephalopathy. Cell transplantation successfully
bridged the 2–10 day time lag patients have to wait for liver
transplants. Similarly, encouraging results have also been
reported for patients with chronic liver failure, with more than
20 patients treated so far. Patients bore decreased ammonia
levels and controlled encephalopathy for 6 weeks after a single
infusion, and for 6 months after 10 direct intrasplenic transplan-
tations (for review [3]). Hepatocyte transplantation has also dem-
onstrated its efﬁciency in correcting metabolic disorders, using
either allotransplantation [5], or genetically modiﬁed autologous
hepatocytes [6]. The potential advantages of the cell-transplanta-
tion technology include a relatively low cost, a demonstrated
feasibility, and the need for a relatively small number of hepato-
cytes; these cells are isolated from untransplantable human liver
segments and are either directly infused in the portal vein or
spleen, or cryopreserved until needed. Moreover, alternative
approaches in using hepatic progenitors [7], bone marrow stem
cells [8], in vitro expansion of hepatocytes or immortalized hepa-
tocytes [9] are under investigation. However, the relative capabil-
ity of these cell types to engraft and repopulate the liver has not
yet been assessed. To date, mature hepatocytes appear to be10 vol. 52 j 150–152
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more efﬁcient than progenitors or stem cells for liver repopula-
tion [7]. In addition, immortalized hepatocytes display karyotypic
instability over time of culture, thus limiting their clinical use
[10].
Hepatocyte transplantation is likely to become a valuable clin-
ical tool to improve the treatment of liver failure. Currently, its
main limitation as a curative treatment of chronic and metabolic
disorders concerns the long term survival of differentiated hepa-
tocytes after cell transplantation, as this is a necessary require-
ment for the maintenance of speciﬁc liver functions.
Hepatocytes are attachment-dependent cells and degenerate rap-
idly without optimal media, extracellular matrix and cell–cell
contact. To survive, they need proper microenvironmental struc-
tures and signals. Moreover, as pointed out by Navarro-Alvarez
and colleagues in this issue of Journal of Hepatology [1], cirrhotic
patients harbour altered architectures that are not considered as
appropriate for hepatocyte transplantation. To solve these issues,
cell transplantation needs to evolve towards transplantable tis-
sue engineering.
Transplantations of engineered hepatic tissue using different
polymer structures have been reported before. Kim and col-
leagues demonstrated in vitro the long term survival of hepato-
cytes in polymer scaffold in 1998 [11], followed in 1999 by
Kaufmann et al. reporting cell survival after transplantation of a
polymeric structure in rats [12]. In 2006, Yokoyama and col-
leagues assayed a bFGF-releasing polymer that allowed hepato-
cyte survival in the subcutaneous cavity for up to 120 days [13].
Recently, Soto-Gutierrez and colleague reported that 60% of mice
survived after 30 days following 90% hepatectomy, while 0% sur-
vived in the control group (implantation of the 3D matrix without
hepatocytes). This establishes the efﬁciency of this technology in
improvingmice survival after 90% hepatectomy [14]. The paper by
Navarro-Alvarez and colleagues goes further in establishing the
in vitro and in vivo proof of concept, as it is one of the few if not
unique works presenting the advantage of tissue engineered
replacement strategy in both acute and chronic liver failure [1].
Two other strategies are currently under investigation, either
as a support or as a replacement for liver transplantation inter-
ventions, namely extracorporeal bioartiﬁcial livers and extracor-
poreal liver assisted devices. Bioartiﬁcial liver is an external
bioreactor containing living hepatocytes and allowing patient
bloodstream to go through for detoxiﬁcation [15]. Several clinical
trials were carried out using such devices, with either hepato-
cytes from porcine [16], and human [17] origin, or hepatoma-
derived cells [17]. These studies showed the safety of the devices
on patients with fulminant hepatic failure; they decreased biliru-
bin and ammonia levels, and to some extent, provided survival
beneﬁt. The main problem associated with the clinical use of
these bioreactors is the scale-up requirement of a device contain-
ing at least 1010 live hepatocytes. The extracorporeal liver assist
devices are an outcome of the recent evolution of various dialysis
systems in use since the early 1970s and are based on the scav-
enging power of albumin. Albumin dialysis against albumin-con-
taining solution across a highly permeable high-ﬂux membrane
gave rise to several devices such as the Molecular Adsorbent
Recirculation System (MARS), the Single-Pass Albumin Dialysis
(SPDA), and the Fractionated Plasma Separation and Adsorption
(FPSA) also called Prometheus. Most clinical studies, performed
in acute liver failure or in acute chronic liver failure, demon-
strated biochemical improvements in terms of bilirubin, bile
acids, creatine, and ammonia levels [18,19]. For patients withJournal of Hepatology 201an acute chronic liver failure, these improvements were accom-
panied with a decrease in hepatic encephalopathy grade and, in
some cases, a slight survival beneﬁt [19,20]. However, it is still
unclear whether there is a real beneﬁt for the mortality rate. In
addition, the long-term application of these devices, as for biore-
actors, is problematic due to technical limitations and costs.
For this reason, intracorporeal cell-based therapy is one of the
most promising technologies under investigation. The article by
Navarro-Alvarez and colleagues clearly establishes the clinical
advantage of tissue engineering for acute and chronic liver failure,
and will be a great help in the designing of routine applications of
cell therapies for liver diseases. Naturally, even if this technology
offers great promises, the fact remains that there is a need for new
active molecules that can be administrated to patients with acute
and chronic liver failure in order to promote liver regeneration.
The molecular and cellular mechanisms leading to liver regenera-
tion after partial hepatectomy are well characterized, but the
mechanisms leading to regeneration in chronic liver diseases
remain to be clariﬁed, thus making it difﬁcult to design molecules
with therapeutic properties. At present, the only molecule to be
recognized and routinely used in clinics against acute fulminant
hepatitis is N-acetyl-cysteine (NAC). Worldwide, NAC is adminis-
trated to patients with acetaminophen-induced fulminant hepati-
tis and new lines of evidence suggest it has therapeutic properties
in non-acetaminophen-induced hepatic failure [21]. There is an
urgent need for new therapeutic molecules not only in the treat-
ment of fulminant hepatitis but also in chronic hepatic failure.
Until such molecules become available, tissue engineering is a
top contender in the list of therapeutic tools for the near future.
The rapid progress in our understanding of stem and progenitor
cell biology – where important insights have been made into
the factors and growth conditions that govern their activation
and differentiation into hepatocytes – associated with the recent
improvements in tissue engineering technology, may just be the
life-saving solution for numerous patients.References
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